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acuity during follow-up, which ranged
from a minimum of 3 years to a
maximum of 17 years (median 5 years).
A similar benefit of PLP has been
reported in a study in which RRD
developed in 2.9% eyes which under-
went PLP in contrast to 24.1% eyes
that did not (Uhumwangho & Jalali
2014). Lack of a control group and
selection bias due to the hospital set-
ting are the major limitations of our
study. Due to retrospective nature of
the study, we cannot predict the inci-
dence of RRD. We recommend PLP
for FC as in our cohort of over 300
eyes this simple prophylactic procedure
helped in maintaining vision with a
very low rate of development of RRD.
Further randomized prospective long-
term studies may provide more evi-
dence to support our recommendation.
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Editor,
T he dexamethasone intravitrealimplant Ozurdex (Allergan, Inc
Irvine, CA) is composed of a matrix of
dexamethasone and a biodegradable
copolymer of lactic and glycolic acids
Fig. 1. (A) For isolated colobomawith normal surrounding retina outside arcade (IdaMann type 5),
the coloboma is entirely surrounded by three rows of the laser. (B) Cases in which the upper margin of
coloboma is touching the superior border of the optic disc (Ida Mann type 2), laser spots are applied
startingfromnasal totheopticdisc.Thennasalmargin is lasered.Temporally laser isperformed inferior
to the presumed inferotemporal vascular arcade. (C) Cases in which the upper margin of coloboma is
superior to the optic disc (IdaMann type 1 fundal coloboma), laser spots are applied initially along the
superior margin of coloboma and then continued along the whole nasal margin. Temporal margin is
lasered inferior to the presumed inferotemporal vascular arcade and superiorly up to superotemporal
arcade sparing the macula. (D) In type 3 coloboma, margins of coloboma are lasered sparing the area
within the temporal vascular arcade and nasally up to 0.5 mm from the disc.
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(Lambiase et al. 2014). The implant
allows the release of 700 g of dexam-
ethasone, providing peak doses at
2 months of injection with a slower
release for up to 6 months. It is
currently used in macular oedema fol-
lowing branch or central retinal vein
occlusion (CRVO), non-infectious pos-
terior uveitis, diabetic macular oedema
and psuedofakic macular oedema
(Lambiase et al. 2014). The implant is
injected 3.5 mm to 4 mm posterior to
the limbus into the mid-vitreous with a
muzzle velocity of 0.8 m/s (Meyer
et al. 2012). Among the complications
of intravitreal injection due to touch or
penetration of adjacent anatomic struc-
tures with the needle tip are retinal
detachment in 0.013% and lens dam-
age in 0.009% of cases. (Meyer et al.
2010, 2011).
A 62-year-old woman with a 2-week
history of CRVO in the left eye and
accidental injection of an intravitreal
dexamethasone implant into the lens
2 days previously in a private practice
presented to our observation. Best-
corrected visual acuity (BCVA) was
20/40. Slit lamp examination showed a
circumscribed area of cataract forma-
tion around the point of penetration of
the implant in the posterior capsular
area of the lens (Fig. 1A). Fundus
examination showed CRVO with cys-
toid macular oedema. Surgical removal
of the crystalline lens and implant was
advised, but the patient refused surgery.
At 1 month of follow-up, BCVA was
20/20 although the patient complained
of disturbed vision due to the position of
the implant in the visual axis (Fig. 1B).
At 8 months of follow-up, the circum-
scribed lens opacity had not expanded
and there were no ophthalmoscopic
signs of CRVO or optical coherence
tomography (OCT) evidence of cystoid
macular oedema. Anterior segment
imaging with rotating Scheimpflug
camera combined with a Placido disc
system (Sirius, CSO Italy) showed the
dexamethasone implant impaling the
posterior lens capsule for approximately
one-fifth of its length with the rest
protruding in the vitreous chamber
(Fig. 2). The study was conducted in
accordance with the Tenets of the Dec-
laration of Helsinki, and the patient
provided consent to the publication of
the present case.
In cases of accidental injection of
the dexamethasone implant in the
crystalline lens, cataract formation
followed by removal of the lens has
been reported (Coca- Robinot et al.
2014). Inefficacy of treatment in these
cases has been attributed to the insuf-
ficient release of the drug due to the
different biochemical properties of the
lens with respect to the vitreous
(Coca-Robinot et al. 2014). In the
case reported herein, macular oedema
resolved, presumably because the dex-
amethasone implant was only partially
inside the lens and protruded into the
vitreous cavity providing sufficient ther-
apeutic levels of dexamethasone. Fur-
thermore, the intralenticular position of
the lens could have given an additional
slow release of dexamethasone as there
were no ophthalmoscopic signs of
CRVO or OCT evidence of cystoid
macular oedema at 8 months of fol-
low-up, which is beyond the reported 6-
month release profile of dexamethasone
in the vitreous cavity (Lambiase et al.
2014). Cataract progression was not
observed over the entire follow-up
period. This could have been because
lens wounds of small size can heal
spontaneously due to the proliferation
of subcapsular epithelium which seals
the wound before the intralenticular
passage of ions and fluid, which is the
cause of cataract progression (Fager-
holm & Philipson 1979).
To our knowledge, this is the first
report in the literature of the intralen-
ticular retention of a dexamethasone
implant with resolution of macular
oedema and no progression of cataract
over 8 months of follow-up.
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(A) (B)
Fig. 1. Slit lamp photographic image of the dexamethasone implant in the lens 2 days (A) and
8 months after accidental injection (B).
Fig. 2. Anterior segment Pentacam image
showing penetration of the dexamethasone
implant in the posterior capsular area of the
lens.
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